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Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2)
DNA in Serum Is a Biomarker of Metastatic Melanoma
Cristiana Lo Nigro1,8, Hexiao Wang2,8, Angela McHugh2, Laura Lattanzio1, Rubeta Matin3, Catherine Harwood3,
Nelofer Syed4, Eleftheria Hatzimichael5, Evangelos Briasoulis5, Marco Merlano6, Alan Evans7,
Alastair Thompson2, Irene Leigh2, Colin Fleming2, Gareth J. Inman2, Charlotte Proby2 and Tim Crook2
Transcriptional silencing of tissue factor pathway inhibitor 2 (TFPI2) occurs in several human tumors including
melanoma. We investigated methylated TFPI2 as a biomarker of metastatic melanoma using qRT–PCR to assess
TFPI2 expression and pyrosequencing to analyze CpG island methylation in malignant melanoma cell lines, in
benign nevi, in 112 primary and metastatic melanomas, and in serum from 6 healthy individuals and 35 patients:
20 patients with primary and 15 patients with metastatic melanoma. The TFPI2 CpG island is unmethylated in nevi
but methylation is associated with metastatic melanoma. Circulating methylated TFPI2 DNA is undetectable in
sera from healthy individuals and detectable in sera from patients with primary and metastatic melanomas, but
the presence of methylated TFPI2 DNA in serum is strongly associated with metastatic disease (Po0.01).
Detection of TFPI2-methylated DNA in the serum of patients with resected melanoma is a sensitive and specific
biomarker of metastatic melanoma. Confirmation of our results in independent patient cohorts would encourage
prospective evaluation as a biomarker of disease state.
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INTRODUCTION
The clinical outcome for patients with advanced melanoma
remains poor despite the availability of new targeted and
immunomodulatory agents (Flaherty, 2012). Management
of metastatic melanoma is, however, undergoing rapid
evolutionary change with the advent of new, targeted
treatments, notably BRAF inhibitors, in the subset of patients
whose melanomas contain mutations in BRAF (Chapman
et al., 2011) and an immunological approach using the anti-
CTLA4 antibody Ipilimumab (Hanaizi et al., 2012). Moreover,
in patients with metastatic melanoma harboring a V600E
BRAF mutation, MEK kinase inhibition may add survival
benefit (Flaherty et al., 2012). With the introduction into
clinical practice of several targeted noncytotoxic therapies for
metastatic melanoma, detection of metastatic disease at early
stages is thought to bear the potential to improve therapeutic
outcome, with an emerging consensus favoring the use of
Ipilimumab early in metastatic disease when patients have a
better performance status, smaller volume of disease, and are
more able to mount an immune response. The use of
Vemurafenib (in cases with V600E BRAF mutations) or
chemotherapy is thereby delayed until disease progression
after Ipilimumab (Flaherty, 2011; Ascierto et al., 2012). An
important implication of this changing landscape of
melanoma management is that patients with metastatic
disease need to be identified much earlier than is currently
possible. Conventional management of patients with high-risk
melanoma (as assessed by traditional histopathological
parameters) entails a watchful waiting strategy, with
restaging radiology reserved for patients presenting with
clinical evidence of metastasis. In the new era, patients
with high-risk lesions will require more regular radiological
monitoring, incurring significant expense and radiation
exposure. In addition, it is recognized that in a proportion of
metastatic melanomas FDG PET CT is poorly diagnostic,
which limits the usefulness of this method for the detection
of metastatic disease (Beasley et al., 2012; Orcurto et al.,
2012). Finally, although many relapsed melanomas do
indeed arise from high-risk primary lesions, a subset of
primary lesions considered at low risk of relapse because of
a low Breslow thickness, nonetheless, ultimately relapse with
metastatic disease. Taken together, these considerations
underline the clinical need for simple, noninvasive tests,
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which can sensitively detect the presence of subclinical
disease and/or early relapse.
It is highly likely that multiple genes undergo genetic or
epigenetic change during transformation of a normal melano-
cyte to melanoma and then to metastatic melanoma (Chin,
2003; Gray-Schopfer et al., 2007). Transcriptional silencing
of tumor suppressor genes has been described in many types
of cancer (Lopez et al., 2009). The relative specificity of
methylation-dependent silencing for cancer suggests that
detection of methylated DNA in biofluids may be useful as
a biomarker in cancer. The use of such epigenetic biomarkers
requires high sensitivity and specificity and validation in large
patient cohorts (Robertson and Wolffe, 2000; Jones, 2012).
Tissue factor pathway inhibitor 2 (TFPI2) is a protein
encoded by the TFPI2 gene, which is located on the reverse
strand of chromosome 7 (ENSG00000105825). TFPI2 has a
number of biological properties that imply that it has
tumor suppressor functions (Kempaiah and Kisiel, 2008;
Gessler et al., 2011; Bretz et al., 2012). TFPI2 is transcrip-
tionally silenced in several human tumors, and methylated
genomic DNA is detectable in the serum of patients with
gastrointestinal cancers (Hibi et al., 2011, 2012). In vulval
squamous cell carcinoma, loco-regional lymph node
metastases can be identified by TFPI2 tissue methylation
(Oonk et al., 2012). In melanoma, methylation in the TFPI2
CpG island was reported to occur exclusively in metastatic
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Figure 1. Representative pyrograms of tissue factor pathway inhibitor 2 (TFPI2) CpG island. (a) The upper two panels are cell lines: WM266.4 (unmethylated)
and SKMel23 (methylated). (b) The lower two panels are clinical cases of melanoma, showing examples of unmethylated (clinical case U) and methylated
(clinical case M) cases.
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disease in one study (Nobeyama et al., 2007), but not in
another (Liu et al., 2008).
As part of a program to identify serum biomarkers
of recurrent/metastatic melanoma, we have analyzed TFPI2
CpG island methylation in a series of melanomas and in
associated patient sera. We show that TFPI2 methylation is a
promising biomarker for metastatic melanoma.
RESULTS
TFPI2 CpG island methylation in melanoma cell lines
In initial experiments, we tested the utility of (quantitative)
pyrosequencing analysis to detect methylation in the TFPI2
CpG island. We designed appropriate primers and assessed
methylation in a panel of 17 malignant melanoma cell lines.
Representative pyrograms are shown in Figure 1a. There was
no methylation in normal melanocytes, but methylation was
detected in 11/17 cell lines (Figure 2a). Next we analyzed the
expression of TFPI2 mRNA using qRT–PCR and observed a
good correlation between methylation as detected by pyrose-
quencing and downregulation of TFPI2 expression (Po0.05;
Figure 2b and c). Pyrosequencing was also consistent with
methylation analysis performed by methylation-specific PCR
(MSP) (Figure 2a). These observations confirm that TFPI2 is a
gene silenced by aberrant methylation in melanoma cell lines
and that pyrosequencing permits sensitive, high-resolution
detection of methylation within the TFPI2 CpG island. To
seek evidence that TFPI2 CpG island methylation might be
associated with metastatic melanoma, we extended these
studies to cell lines for which poorly metastatic parental cell
lines and matched highly metastatic derivative cell lines were
available to us. In WM115 and LM2 parental cell lines, TFPI2
mRNA was expressed and the CpG island unmethylated. In
the metastatic derivatives WM266 and WM293, and LM9 and
LM29, respectively, there was clear reduction in TFPI2 mRNA
(Figure 2d) with a corresponding increase in CpG island
methylation (Figure 2e).
TFPI2 CpG island methylation increases in metastatic melanoma
These results prompted us to determine whether methylation
was present in clinical cases of melanoma of varying meta-
static status, and we proceeded to analyze methylation in a
series of 112 histologically confirmed malignant melanomas,
of which 53 were metastatic and 59 were primary lesions.
Representative pyrosequencing of clinical cases is shown in
Figure 1b. A key requirement of using methylation as a
potential cancer biomarker is that the CpG island of the gene
of interest is unmethylated in normal tissue. Therefore, to
determine background methylation levels in a biologically
0
0.05
0.1
0.15
0.2
Colo829
SKMel2
SKMel23
SKMel30
SKMel147
SKMel173
SBCL2
PMWK
WM35
WM902.6
WM266–4
Normal
0–5% 6–10% 11–20% 21–50% 51–100%
Mel224
Mel505
Mel501
WM239
C8161
A375M
1 2 3 4 5 6 7 8 9
1 2 3 4 5 6 7 8 9
MSP
M
M
U
U
M
M
U
M
U
M
M
M
M
U
M
U
M
U
a
M
el
50
1
C8
16
1
R
el
at
iv
e
TF
PI
2 
m
R
N
A
0
0.5
1
A3
75
M
W
M
23
9
M
el
50
5 0
50
100
M
el
50
1
C8
16
1M
ea
n 
m
et
hy
la
tio
n
A3
75
M
W
M
23
9
M
el
50
5
P < 0.05 
Lo
g 
re
la
tiv
e 
TF
PI
2 
m
R
N
A
0
–2
–4
–6
–8
Methylated
c
Unmethylated
b
d
WM115
LM2
LM29
LM9
WM293
WM266
e
W
W
M
11
5
W
M
26
6
W
M
29
3
LM
2
LM
9
LM
29
TF
PI
2 
m
R
N
A
Figure 2. Tissue factor pathway inhibitor 2 (TFPI2) CpG island methylation, detected by pyrosequencing, correlates with transcriptional downregulation in
melanoma cell lines. (a) Summary of pyrosequencing analysis of TFPI2 CpG island in melanoma cell lines. Pyrosequencing was done as described in Materials and
Methods. As shown, the level of methylation is represented by the degree of shading in the circles, each of which represents an individual CG dinucleotide in the
amplified fragment. Also shown is the result of methylation-specific PCR (MSP) analysis. (b) Representative qPCR analysis of TFPI2 in melanoma cell lines showing
association of CpG island methylation with downregulation of mRNA. (c) Mann–Whitney plot of TFPI2 expression in cell lines with or without CpG island
methylation. Expression is significantly downregulated in cases with CpG island methylation. (d) qPCR analysis of TFPI2 expression in parental and metastatic
derivative cell lines. WM115 parental cells with metastatic derivatives WM266 and WM293 and parental LM2 cells with metastatic derivatives LM9 and LM29
were subjected to qPCR for TFPI2 as described in Materials and Methods. In each case, expression in the metastatic sublines is lower than in the parental lines.
Data shown are means from three experiments±1 SD. (e) Pyrosequencing analysis of TFPI2 CpG island in parental and metastatic melanoma cell lines. In each
case, methylation increases in the metastatic derivatives compared with the parental lines, consistent with qPCR analysis.
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relevant control tissue, we used pyrosequencing to analyze the
TFPI2 CpG island in a series of benign pigmented nevi that
have undergone detailed histopathological analysis to confirm
the absence of melanoma. The level of methylation in the
TFPI2 CpG island was uniformly low in all nevi, with a mean
value of 2% across the analyzed fragment of the CpG island
(Figure 3a). Essentially, similar results were seen in preliminary
analysis of dysplastic nevi (data not shown). Methylation was
detectable in both primary and metastatic melanomas, but the
level of methylation was significantly higher in metastatic
melanoma (Po0.05; Figure 3a and b).
Methylated TFPI2 CpG island DNA: a serum biomarker of
metastatic melanoma
Together, the above data show that although methylation in
TFPI2 is detectable using pyrosequencing in both primary and
metastatic melanomas methylation increases in metastatic
melanomas. These observations prompted us to ask whether
methylated DNA from the TFPI2 CpG island is detectable in
the peripheral blood of patients with melanoma and whether
differences exist between patients with non-metastatic disease
and those with metastatic melanoma. Accordingly, and again
using pyrosequencing, we tested for the presence of methy-
lated genomic DNA from the TFPI2 CpG island in sera from
melanoma patients and from six healthy volunteers. Repre-
sentative quantitative profiles of % methylation at each CG
dinucleotide are shown in Figure 4a, and the frequencies of
detectable methylation in each patient group are shown in
Figure 4b. In healthy individuals, the level of TFPI2 CpG
island methylated genomic DNA was uniformly low
(Figure 4a and b). In patients without known metastases, the
level of TFPI2 CpG island methylated genomic DNA was low
in the majority of patients (Figure 4a and b). However, in
patients with metastatic disease, methylated DNA was present
at higher levels and at a higher frequency than in patients
lacking metastases (Figure 4a and b). For 20 cases, both
tissue and serum were available for analysis, and we com-
pared the detection of methylated TFPI2 DNA (Figure 5a). This
revealed, in general, a good correlation between tissue
and serum. Importantly, no case was positive for methylation
in serum, but it was negative in tissue. TFPI2-methylated
DNA in serum was not related to Breslow thick-
ness (Figure 5b). The differences in serum TFPI2 methylation
between non-metastatic and metastatic melanoma was sig-
nificant (Po0.01; Figure 5c). Finally, we plotted receiver
operator characteristic curves from the 35 sera to determine
the optimal sensitivity:specificity cutoffs for TFPI2 CpG island
methylation in serum to distinguish metastatic disease from
non-metastatic disease (Figure 5d). This analysis revealed that
with a mean methylation cutoff value of 5% in serum the
diagnostic sensitivity for metastatic disease in our series is
85%, with a specificity of 87%.
DISCUSSION
Here, we present data suggesting that methylation in the CpG
island of TFPI2 may have utility as a circulating biomarker of
metastatic melanoma with a high sensitivity and specificity.
We were prompted to test the candidacy of TFPI2 as a serum
biomarker following reports that methylation of this CpG
island of this gene is specific to metastasis in melanoma
(Nobeyama et al., 2007) and our own observations shown
herein that methylation increases significantly in metastatic
melanoma, both in cell lines and in clinical cases.
In initial studies in a panel of melanoma cell lines,
we demonstrated methylation-dependent transcriptional
silencing of TFPI2 in both metastatic and non-metastatic
melanoma cell lines with a good correlation between methyl-
ation and mRNA downregulation. However, analysis of
non-metastatic parental WM115 and LM2 cells, with their
respective metastatic derivatives, showed clear acquisition of
TFPI2 CpG island methylation with increasing metastatic
potential.
Analysis of a series of control benign pigmented nevi
showed that methylation was uniformly low, implying that
methylation is specific to neoplastic melanocytes, and in a
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Figure 3. Analysis of tissue factor pathway inhibitor 2 (TFPI2) CpG island
methylation in (benign) pigmented nevi and malignant melanoma. (a) TFPI2
CpG island methylation is specific to melanoma and increases in metastatic
melanoma. Pyrosequencing was done as described in Materials and Methods.
As shown, the level of methylation is represented by the degree of shading in
the circles, each of which represents an individual CG dinucleotide in the
amplified fragment. The CpG island is unmethylated in nevi and increases with
acquisition of a metastatic phenotype in melanoma. (b) Mann–Whitney
analysis of TFPI2 CpG island methylation in pigmented nevi, primary
melanomas, and metastatic melanomas showing significantly increased
methylation in metastatic melanoma.
CL Nigro et al.
TFPI2 Is a Serum Biomarker in Melanoma
www.jidonline.org 1281
well-annotated clinical series containing approximately equal
numbers of metastatic and non-metastatic melanomas we
observed TFPI2 CpG island methylation in both primary and
metastatic melanomas. There was, however, a significant
increase in methylation in the metastatic cases. Our data
are, therefore, somewhat at variance with those of Nobeyama
et al. (2007), who reported TFPI2 CpG island methylation to
occur exclusively in metastatic lesions. The explanation for
this is not clear, but may reflect the different analytical
techniques used. Nonetheless, both studies reveal a strong
association of TFPI2 silencing with metastatic melanoma, and
this is reinforced by our studies of TFPI2 expression and CpG
island methylation in WM115 and LM2 parental cell lines and
their metastatic derivatives.
Pyrosequencing quantitatively determines the level of cyto-
sine methylation at individual CG dinucleotides and affords a
higher level of resolution than techniques such as MSP. There
are, however, few reports of the use of pyrosequencing to
analyze biofluids for the presence of methylated DNA. We
therefore wished to evaluate whether pyrosequencing can
quantitatively determine the level of TFPI2-methylated DNA
in serum, and we analyzed a series of sera obtained from
patients at the time of diagnosis of metastatic disease. As a
comparator group, we analyzed patients from the same
clinical practice who at the time of sampling did not have
metastatic disease. In control sera from healthy volunteers,
methylation was extremely low. In melanoma patients, we
observed that the presence of TFPI2 CpG island methylated
DNA in serum is strongly associated with metastatic mela-
noma. Notwithstanding the relatively small numbers in this
initial study, we have shown therefore that TFPI2 CpG island
methylation in serum, as detected by pyrosequencing, permits
the identification of patients with metastatic melanoma with a
high sensitivity and specificity.
The sera we have analyzed are from distinct groups of
patients with and without metastatic disease at the time of
sampling and several key questions raised by our results
require resolution in order to confirm the biomarker utility of
TFPI2. First, in patients who have undergone potentially
curative excision of primary melanomas, does the appearance
of methylated DNA in serum precede the development of
metastatic disease, and if so by how long? Hibi et al. (2012)
have previously shown that TFPI2-methylated DNA became
undetectable in serum following curative resection of
colorectal carcinomas, and it will clearly be important to
address this issue in melanoma. Second, how do levels of
methylated DNA in serum change after resection of metastatic
lesions? Third, is the presence of subclinical metastasis marked
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by continuously increasing the levels of methylated DNA in
serum or simply by exceeding a predefined threshold level? To
address these issues, we are currently performing ongoing,
prospective sequential serum monitoring in individual patients
during their regular clinical follow-up after surgical removal of
primary and metastatic lesions to (i) determine whether
increase in the levels of methylated TFPI2 genomic DNA is
invariably associated with disease recurrence and/or
metastasis, (ii) to more clearly define how changes in the
level of methylated TFPI2 genomic DNA correlate with
disease activity, and (iii) to map time-dependent changes in
the levels of methylated DNA after surgical removal of
melanoma. Such studies will be critical in defining how the
analysis of methylated DNA in serum can be most usefully
deployed in the clinical management of melanoma patients.
Finally, the numbers of sera analyzed in this initial study are
small and the results require independent verification in larger
patient cohorts. Confirmation of our results would support the
use of TFPI2 as a cheap, noninvasive test for the early
detection of metastatic melanoma. Such biomarkers will
become increasingly required as the treatment landscape of
metastatic melanoma moves toward early use of biological
and targeted therapies. In conclusion, we present evidence
that the presence of TFPI2-methylated genomic DNA in the
serum of melanoma patients may have utility in the detection
of metastatic disease.
MATERIALS AND METHODS
Cell lines
Melanoma cell lines were routinely grown in DMEM or RPMI,
supplemented with 10% fetal bovine serum. Primary, normal human
melanocytes were purchased from Lonza (Walkersville, MD) and
grown according to the manufacturer’s instructions. All cells were
incubated at 37 1C and 5% CO2, with regular mycoplasma contam-
ination testing. The characteristics of the cell lines are summarized in
Table 1. Genomic DNA was isolated from cell pellets using the
QIAamp DNA mini kit (Qiagen, Crawley, UK) according to the
manufacturer’s instructions. Total RNA was isolated using the RNeasy
mini kit (Qiagen, Crawley, West Sussex, UK). cDNA was synthesized
from 1mg of total RNA using the high capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Carlsbad, CA).
Tissues
The study received approval from the Local Research Ethical
Committee, East London and City Health Authority and the Tayside
Tissue Bank under delegated authority from the Tayside Local
Research Ethics Committee and adhered to the Helsinki Guidelines.
Tissues were obtained under written, informed consent. Melanomas
(comprising 53 primary lesions and 59 metastases) and benign nevi
(n¼ 10) were from the Pathology archives of Bart’s and the London
NHS Trust and from the Tayside Skin Cancer Tissue Bank. All tissues
underwent histopathological review before inclusion in the study to (i)
confirm the diagnosis of melanoma, (ii) to confirm Breslow thickness,
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and (iii) to verify sufficient representation of neoplastic cells.
Melanomas were both primary cutaneous and metastatic lesions.
Surgical excision was performed according to routine protocols
of clinical care. Recurrent melanomas were typically from lymph
node resections (where performed), sentinel lymph node biopsies,
or cutaneous recurrences. As control tissues, we analyzed in
parallel a series of benign pigmented nevi and dysplastic nevi
obtained from routine surgical excisions of sun-exposed skin. The
diagnosis and the absence of melanoma was confirmed by expert
histopathological review before inclusion in the study. Genomic
DNA was obtained from formalin-fixed paraffin-embedded tissue
sections by extended digestion in proteinase K, followed by phenol
extraction.
Sera
Sera were collected from patients (n¼ 35) at the time of diagnosis
of metastatic disease or during routine follow-up in patients with no
clinical evidence of metastasis. Control sera were from six healthy
individuals. All sera were harvested using a predefined, standard
protocol. Serum was prepared from peripheral blood by centrifuga-
tion, and then snap frozen in aliquots that were stored at  80 1C
until thawed for the preparation of genomic DNA. Aliquots (200ml)
of serum were batch thawed on ice immediately before use, and
genomic DNA was isolated using the QIAamp DNA Blood Mini
kit (Qiagen). The quality and integrity of isolated DNA was verified
by amplification of control genes b-actin and GAPDH, and the
DNA was then subjected to sodium bisulphite modification as
described below.
Analysis of methylation
Genomic DNA from cell lines, tissue samples, and sera was subjected
to bisulphite modification using the EZ DNA Methylation Kit (Zymo,
Irvine, CA) according to the manufacturer’s instructions. After
bisulphite modification, methylation in the CpG island of the TFPI2
gene was analyzed by pyrosequencing, in which the degree of
methylation at each CG position in a sequence is determined from
the ratio of T and C. Primer sequences were as follows:
Forward: 50-GGGTTTATGGTGTAGGGGG-30
Reverse: 50-CAACCACCCCTCAAACTCC-30 biot
PCR conditions were 95 1C for 10 minutes, 95 1C for 30 seconds/
57 1C for 30 seconds/72 1C for 40 seconds for 40 cycles, and 72 1C for
7 minutes. PCR products were resolved through 2% agarose gels,
visualized using a transilluminator, and then analyzed by pyrose-
quencing using the Biotage Sample Prep kit (Diatech, Jesi, Italy) and
the forward primer for sequencing. Analysis of percentage methyla-
tion at each CG dinucleotide was performed using the Pyromark Q
CpG Software (Qiagen). Placental DNA was used as negative control
of methylation (0% average methylation), and a commercial methyl-
ated DNA (Millipore, Billerica, MA) was used as positive control
(98% average methylation). Methylation was also analyzed by MSP.
DNA (0.5mg) was modified by sodium bisulphite using the Zymo EZ
DNA methylation kit (Molecular Devices, Sunnyvale, CA). Bisulfite-
modified DNA was used as a template for PCR with primers specific
for unmethylated and methylated alleles. EpiTect control DNA
(methylated and unmethylated) was used as a positive and negative
control in each experiment. MSP primer sequences:
Forward M primer: 50-TATGGTTCGTTGCGTTTTTTTCGTC-30
Reverse M primer: 50-CGCTCGCCCCCTAAAACTATCGAT-30
Product size: 140 bp
Forward U primer: 50-ATGGTTTGTTGTGTTTTTTTTGTTG-30
Reverse U primer: 50-CCACTCACCCCCTAAAACTATCAAT-30
Product size: 140 bp
Gene expression
PCR reactions (20ml) were performed using cDNA obtained by
reverse transcription. Amplification and analysis were done
according to the manufacturer’s protocol in 96-well plates in an
ABI PRISM 7000 Sequence Detection System (Applied Biosystems)
and the pre-cast ‘‘TaqMan Gene Expression Assays’’ (Applera, https://
products.appliedbiosystems.com/) for TFPI2 (Hs00197918_m1).
Quantification of the target transcript was performed in comparison
with the reference transcript b2microglobulin (Hs99999907_m1),
using the ‘‘delta-delta Ct method for comparing relative expression
results in real-time PCR as outlined by PE Applied Biosystems (Perkin
Elmer, Forster City, CA).
Statistics
Statistical analyses were performed using Prism 5 (GraphPad
software, La Jolla, CA, USA). Unpaired Mann–Whitney t-test
was used to compare methylation levels between different groups
for both cell lines and tissue samples. Receiver operator characteristic
curves were constructed by plotting sensitivity versus 1-specificity
at various mean % CG methylation values determined by
pyrosequencing.
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Table 1. Characteristics of melanoma cell lines
Cell line Description B-raf/N-ras TFPI2
HEMA Normal human melanocytes Wt/Wt U
SBCL2 RGP Wt/Q61L U
PMWK Early RGP Wt/Wt M
WM-35 RGP V600E/Wt M
WM-902.6 SSM VGP V600E/Wt M
SKMel224 VGP Wt/Q61R U
SKMel505 VGP Wt/Wt M
WM-266-4 Metastatic melanoma V600D/Wt U
SKMel2 Metastatic melanoma Wt/Q61R U
SKMel23 Metastatic melanoma G466A/Wt M
SKMel30 Metastatic melanoma Wt/Q61R M
SKMel147 Metastatic melanoma Wt/Q61R U
SKMel173 Metastatic melanoma Wt/Q61K M
SKMel501 Metastatic melanoma V600E/Wt M
COLO-829 Metastatic melanoma V600E/Wt M
C8161 Metastatic melanoma Wt/Wt U
WM239A Metastatic melanoma V600D/Wt M
A375M Metastatic melanoma V600E/Wt M
Abbreviations: M, methylated; RGP, radial growth phase; SSM, superficial
spreading melanoma; VGP, vertical growth phase melanoma; U, unmethy-
lated; Wt, wild-type.
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